Hot valuations take the shine off mid-to-long-term targets
09/09/26 -"The mid-to-long term targets announced on Capital Markets Day yesterday, despite being commendable, could not excite investors. This is because Sandoz’s expensive valuations already incorporate ..."
Pages
57
Language
English
Published on
09/09/26
You may also be interested by these reports :
09/09/26
The mid-to-long term targets announced on Capital Markets Day yesterday, despite being commendable, could not excite investors. This is because ...
08/09/26
The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term ...
04/09/26
While we have tweaked our earnings estimates slightly higher, the decline in our target price is owing to the removal of a peer which was skewing the ...
04/09/26
We have tweaked our earnings estimates lower and considering the recent late-stage setbacks for cardiovascular (Wainua) and oncology (Volrustomig) ...